Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to a sulphonamide compound, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
• Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C), Cys-Cys (C-C) and Cys-X 3 -Cys (C-X 3 -C) families.
• the C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues.
• the C-X 3 -C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.
• the C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
• IL-8 interleukin-8
• NAP-2 neutrophil-activating peptide 2
• the C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l and l ⁇ (MIP-1 and MIP-1 ⁇ ), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22).
• MCP-1 human monocyte chemotactic proteins 1-3
• MCP-2 and MCP-3 RANTES (Regulated on Activation, Normal T Expressed and Secreted)
• eotaxin and the macrophage inflammatory proteins l and l ⁇ MIP-1 and MIP-1 ⁇
• TARC Thymus and Activation Regulated Chemokine
• MDC Macrophage Der
• the C-X 3 -C chemokine (also known as fractalkine) is a potent chemoattractant and activator of micro glia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.
• G protein-coupled receptors among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX 3 CR1 for the C-X 3 -C family.
• These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
• US patent 5,962,490 discloses a series of sulphonamide compounds said to be useful for treating endothelin mediated diseases. There is no specific disclosure of pyrazine sumphonamides and no mention of chemokine mediated diseases.
• the present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:
• R 1 , R 2 and R 3 are independently hydrogen, halogen, cyano, CF 3 , or C 1-6 alkyl;
• R 4 is halogen, CO 2 R 12 ,
• alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
• OC 1-6 alkylR 11 or OC 2-6 alkyl-X-R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 ;
• R 5 and R 6 are independently hydrogen, cyano, halogen, CO2R 12 , CONR 14 R 15 ; C 1-6 alkyl optionally substituted by hydroxy, NR 14 R 15 , or 1-3 fluorines;
• n 1 ,2, 3, 4 or 5;
• q 2, 3, 4, 5 or 6;
• X is NR 13 , O, S, S(O), S(O) 2 ;
• R 12 and R 13 are independently hydrogen or C ⁇ -6 alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;
• R 14 and R 15 are independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl or (CH 2 )qOH, or R and R together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl, C 1-6 alkyl-OH, or hydroxy; and
• aryl includes phenyl and naphthyl.
• alkyl whether alone or as part of another group, includes straight chain and branched chain alkyl groups.
• Examples of 5- to 7-membered heteroaromatic ring containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl.
• saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.
• Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
• the thienyl moiety is linked to the sulphonamide at the 2-position of the thiophene ring.
• R , R and R are chloro or bromo.
• R , R and R are all hydrogen or two are hydrogen and the other is chloro, bromo or methyl. More preferably R 2 and R 3 are hydrogen and R 1 is chloro at the 5-position of the thienyl ring.
• examples of C 3-6 alkynyloxy include OCH 2 CCH
• examples of O -6 alkyl-O-C 1-6 alkyl include OCH 2 CH 2 OMe
• examples of OC 1-6 alkylR 11 include OCH 2 R ⁇
• examples of OC 1-6 alkylR 16 include OCH 2 pyrrolidine.
• R 4 examples include C 1-6 alkoxy such as methoxy and ethoxy, phenoxy, 2- furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2- pyridylmethoxy, 3-pyridazmylmethoxy, methoxy, 2-(l-imidazolyl)ethoxy and 4- methoxyphenylmethoxy. More preferably R 4 is methoxy or pyridylmethoxy. Most preferably R 4 is methoxy.
• NR 14 R 15 includes morpholine, pyrrolidine, NMe 2 , NHCH 2 CH 2 OMe, NHMe, and the groups below:
• Examples of X-(CH 2 )qNR 14 R 15 includes SCH 2 CH 2 NH 2 and SCH 2 CH 2 NMe 2
• examples of (CH 2 )nNR 14 R 15 include CH 2 morpholine
• examples of X-R 12 includes SMe, OMe, OEt, OH, SO 2 Me
• examples of X-C 1-6 alkylR 16 includes OCH pyrrolidine
• examples of X- (CH 2 )nCO 2 R 12 includes SCH 2 CO 2 H, SCH 2 CO 2 Me, SCH 2 CH 2 CO 2 Me
• examples of X- (CH 2 )nCONR 14 R 15 includes SCH 2 CONH 2 , SCH 2 CONHMe, SCH 2 CONMe 2
• examples of X-(CH 2 )nR ⁇ includes the groups below:
• Examples of X-(CH 2 )nCN includes SCH 2 CN, examples of X-(CH 2 )qOR 12 includes OCH 2 CH 2 OMe, examples of (CH 2 )nOR 12 includes CH 2 OH, CH 2 OMe, examples of X-(CH 2 )qNHC(O)NHR 12 includes SCH 2 CH 2 NHC(O)NHEt, and examples of X-(CH 2 )qNHC(O)R 12 includes NHCH 2 CH 2 NHC(O)Me.
• R 5 examples include hydrogen, halogen such as bromo and chloro, phenyl, C e alkyl such as methyl, cyano and 2-aminothanethiol. More preferably R 5 is hydrogen, methyl or halogen such bromo or chloro.
• Preferred groups for R 6 include hydrogen, C 1-6 alkyl and halogen, more preferably hydrogen, methyl, and chloro.
• Preferred compounds of formula (I) include: N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide N-(5-Bromo-3-ethoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide N-(5-Bromo-3-methoxy-2-pyrazinyl)-4,5-dichloro-2-thiophenesulphonamide 5-Chloro-N-(3-methoxy-5-phenyl-2-pyrazinyl)-2-thiophenesulphonamide N-(5-Bromo-3-phenoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide N-[5-Bromo-3-(2-furanylmethoxy)-2-pyrazinyl]-5-chloro
• R 1 , R 2 and R 3 are independently hydrogen, C 1-6 alkyl or halogen
• R 4 is halogen, Cue alkoxy or OR 9 ;
• R 5 and R 6 are independently hydrogen, halogen, C 1-6 alkoxy, C 1-6 alkylthio, cyano, R 9 , OR 9 , NR 9 R 10 , SR 9 , S(CH 2 ) n CO 2 H, S(CH 2 ) n CO 2 R 12 , S(CH 2 ) n CONR 12 R 13 , S(CH 2 ) n R 1 ! or a
• n 1, 2 or 3;
• R 9 and R 10 are independently hydrogen, C 1-6 alkyl optionally substituted by hydroxy, C 1-6 alkoxy or NHCOC 1-6 alkyl, or R 9 and R 10 are optionally substituted aryl, C 1-6 alkyl-aryl or
• C 1-6 alkyl-R 11 or R 9 and R 10 together with the nitrogen atom to which they are attached form a 4- to 8-membered saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl or Cue alkyl-OH; and
• R 11 is a 5- to 7-membered heteraromatic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C 1-6 alkyl;
• R 12 and R 13 are independently hydrogen or C 1-6 alkyl.
• the thienyl moiety is preferably linked to the sulphonamide at the 2-position.
• R 1 , R 2 and R 3 are independently hydrogen, C 1-6 alkyl or halogen, preferred halogen groups being chloro or bromo.
• R 1 , R 2 and R 3 are all hydrogen or two are hydrogen and the other is chloro, bromo or methyl. More preferably R 2 and R 3 are hydrogen and R 1 is chloro at the 5 -position of the thienyl ring.
• R 4 preferred groups for R 4 include C 1-6 alkoxy such as methoxy and ethoxy, phenoxy, 2-furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3- isoxazolyl)methoxy, 2-pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, and 2-(l- imidazolyl)ethoxy.
• R 5 For sub-class (IA) preferred groups for R 5 include hydrogen, halogen such as bromo and chloro, phenyl and C 1-6 alkyl such as methyl.
• R 6 preferred groups for R 6 include hydrogen, C 1-6 alkyl and halogen, more preferably hydrogen, methyl and chloro.
• preferred compounds include those of examples 1 to 32 exemplified herein, both in free acid form and in the form of pharmaceutically acceptable salts.
• R 4 , R 5 and R 6 are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):
• Preferred leaving groups LG include halogen such as chloro.
• the reaction between compounds (II) and (III) is carried out by treating compound (II) with a base such as sodium hydride or potassium tert-butoxide in a suitable solvent such as 1,2- dimethoxyethane or tetrahydrofuran.
• R 4 is C 1-6 alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group; C 3-6 alkenyloxy or C 3-6 alkynyloxy where either may be optionally substituted with hydroxy or NR 14 R 15 ; OCue alkyl-X-C ⁇ -6 alkyl where the alkyl groups may form a 3-6 membered saturated ring; OCu ⁇ alkylR 11 , or OC 2 .
• alkyl-X-R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 ; or OC 1-6 alkylR 16 ;
• compounds of formula (II) can be prepared by treating a compound of the formula (IV), where LG is a leaving group (such as chlorine or bromine):
• a suitable solvent such as 1,2-dimethoxyethane, NN-dimethylformamide or tetrahydrofuran
• a suitable base such as sodium hydride or potasssium tert-butoxide at a suitable temperature such as 25°C to 60°C.
• R 4 is Cue alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
• OCue alkylR 11 or OC 2 .
• 6 alkyl-X-R 11 where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR 14 R 15 , SR 13 , S(O) 2 R 13 , S(O)R 13 ; or OC ⁇ . 6 alkylR 16 ; compounds of formula (I) can be prepared by treating a compound of the formula (VI), where LG is a leaving group (such as chlorine or bromine):
• a suitable solvent such as 1,2-dimethoxyethane, N,N-dimethylformamide or tetrahydrofuran
• a suitable base such as sodium hydride or potasssium tert-butoxide at a suitable temperature such as 25°C to 60°C.
• Compounds of structure (Vlll) can be prepared by taking a compound of formula (Vll) where LG is a leaving group (such as chlorine or bromine) and protecting the sulfonamide as for example the trimethylsilyethoxymethyl ether (SEM) or methoxymethyl ether
• R 5 -H is a primary or secondary amine, thiol or alcohol as defined above (i.e. where R 5 is a group containing an X moiety where X is NR 13 , O or S), in a suitable solvent (such as tetrahydrofuran or acetonitrile) with or without a suitable base (such as sodium hydride, caesium carbonate or triethylamine) at a suitable temperature ranging from 25-85°C to afford compound of the formula (X):
• a suitable solvent such as tetrahydrofuran or acetonitrile
• a suitable base such as sodium hydride, caesium carbonate or triethylamine
• the protecting group (P) can then be removed by standard methods to afford compound of formula (1).
• Compounds of structure (11) or (1), where R 5 is an optionally substituted aryl or heteroaryl ring as defined in the claims, can be prepared by taking a compound of formula (XI) or (VII) where LG is a suitable leaving group such as bromine, chlorine or iodine and reacting it with an aryl or heteroaryl boronic acid such as phenyl boronic acid, a palladium catalyst such as [l, -bis(diphenylphosphino)ferrocene]palladium (11) chloride, a suitable base such as cesium fluoride, sodium acetate or cesium carbonate and a suitable solvent such as methanol or ethanol and heating between 40-80°C
• R 5 or R 6 is CO 2 R 13
• R 13 can be prepared by reacting a compound of formula (11) or (1), where R 5 or R 6 is bromine or iodine, in a suitable solvent such as R 13 OH or dioxane containing R 13 OH, a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1 , 1 '- bis(diphenylphosphino)ferrocene]palladium (11) chloride under an atmosphere of carbon monoxide usually at 2-10 barr, ideally at 4-6 barr and at a temperature of 70-120 °C.
• a suitable solvent such as R 13 OH or dioxane containing R 13 OH
• a suitable tertiary amine such as triethylamine
• a suitable palladium catalyst such as [1 , 1 '- bis(diphenylphosphino)ferrocene]palladium (11) chloride under an atmosphere of
• Compounds of formula (11) and (1) where R 5 or R 6 is CONR 14 R 15 can be prepared by reacting a compound of formula (11) or (1), where R 5 or R 6 is bromine or iodine, in a suitable solvent such as dioxane containing NHR 14 R 15 , a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1'- bis(diphenylphosphino)ferrocene]palladium (11) chloride under an atmosphere of carbon monoxide usually at 2-10 barr, ideally at 4-6 barr and at a temperature of 70-120 °C.
• a suitable solvent such as dioxane containing NHR 14 R 15
• a suitable tertiary amine such as triethylamine
• a suitable palladium catalyst such as [1,1'- bis(diphenylphosphino)ferrocene]palladium (11) chloride under an atmosphere of carbon monoxide usually at
• Compounds of formula (1) where R 5 or R 6 is CHO can be prepared from compounds of formula (1) where R 5 or R 6 is CH 2 OH by oxidation using a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50°C.
• a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50°C.
• R 5 or R 6 is CH(OH)R 11 or CH(OH)(C 1 -5)alkyl
• R 5 or R 6 is CHO by reaction with a compound of formula (XII) where M is a metal such as magnesium or lithium in a suitable solvent such as tetrahydrofuran or diethyl ether at a temperature of 0-10°C
• the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or -toluenesulphonate.
• a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine
• an acid addition salt such as a hydrochloride, hydrobromide, phosphate
• the compounds of formula (I) has activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.
• conditions/diseases include:
• obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
• COPD chronic obstructive
• Neurodegenerative diseases and dementia disorders e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt- Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntingdon's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g.
• multiple sclerosis multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis
• neuromuscular disorders e.g. myasthenia gravis and Lambert- Eaton syndrome
• spinal diorders e.g. tropical spastic paraparesis
• stiff-man syndrome paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis
• CNS trauma migraine
• stroke and correctum diseases such as meningitis
• AIDS Acquired Immunodeficiency Syndrome
• lupus erythematosus systemic lupus, erythematosus, Hashimoto's thyroiditis
• type I diabetes nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia pupura
• post-operative adhesions and sepsis.
• Cancer carcinoma & tumour metastasis, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma.
• NSCLC non-small cell lung cancer
• Hematopoietic tumors of lymphoid lineage including acute lymphocytic leukemia, B cell lymphoma and Burketts lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia.
• Hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias and promyelocytic leukemia.
• Tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
• Reproductive Diseases e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis
• infectious diseases such as HIV infection and other viral infections, bacterial infections.
• the present invention provides a compound of formula (I), or a pharmaceutically- acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
• the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.
• Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.
• the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
• the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.
• the term “therapy” also includes “prophylaxis 1 " unless there are specific indications to the contrary.
• the terms “therapeutic” and “therapeutically” should be construed accordingly.
• the invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
• the invention also provides a method of treating a respiratory disease, such as athma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
• a respiratory disease such as athma and rhinitis, especially asthma
• the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
• the compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
• the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
• compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
• the compound of the invention is administered orally.
• 5-Bromo-3-methoxy-2-pyrazinamine (l.Og) in 1,2-dimethoxyethane (lOmL) was added to a stirred suspension of sodium hydride (0.48g of 60%) in 1,2-dimethoxyethane (lOmL) under nitrogen at room temperature.
• 5-Chloro-2-thienylsuphonyl chloride (l.lg) in 1,2- dimethoxyethane (lOmL) was added drop wise over 30 minutes. After 1 hour, aqueous citric acid (50mL of 5%) was added and the product extracted with ethyl acetate (X3). The combined extracts were washed with saturated brine, dried (MgSO 4 ) and the solvent was evaporated.
• Example 23a Prepared by the method of Example 20b using pyridazine-3 -methanol and 5-chloro-N-(3- bromo-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide (Example 23a). m/e 398 (M+l + , 100%)
• step 30a The product from step 30a (0.26g), 2-mercaptoethylamine hydrochloride (0.07g) and cesium carbonate (0.41g) in acetonitrile (10ml) was stirred at room temperature and under nitrogen for 20 hours. The reaction mixture was partitioned between ethyl acetate and water. The ethyl acetate solution was then washed with brine, dried (MgSO 4 ) and evaporated.
• CHO-K1 cells stably expressing the human recombinant CCR4 receptor (Euroscreen; Brussels, Belgium) were cultured in NUT.MLX.F_12(HAM) medium with glutamax-1, containing 10% (v/v) foetal bovine serum and 400 ⁇ gml "1 geneticin.
• Cells were harvested at approximately 70% confluence by treatment with a cell dissociation buffer, and seeded at 5xl0 3 cells/lOO ⁇ l culture medium into wells of a black Costar clear-bottomed 96-well microtitre plates. Plates were incubated overnight at 37°C in 5% CO 2 and used the following day.
• HBSS Hanks balanced salt solution
• Example 23 pIC 5 o 8.0
• Example 16 pIC 5 o 6.2
• All the compounds of the examples have a pIC 50 of less than 5.0.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pulmonology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)
• Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)

Priority Applications (6)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26655646

Family Applications (1)

Country Status (7)

Cited By (20)

Families Citing this family (4)

Citations (2)

Family Cites Families (1)

• 2002
  • 2002-12-17 JP JP2003552754A patent/JP2005516936A/ja active Pending
  • 2002-12-17 AU AU2002358390A patent/AU2002358390A1/en not_active Abandoned
  • 2002-12-17 WO PCT/SE2002/002355 patent/WO2003051870A1/en not_active Ceased
  • 2002-12-17 US US10/499,102 patent/US7410972B2/en not_active Expired - Fee Related
  • 2002-12-17 EP EP02792158A patent/EP1458715B1/en not_active Expired - Lifetime
  • 2002-12-17 DE DE60207890T patent/DE60207890T2/de not_active Expired - Fee Related
  • 2002-12-17 AT AT02792158T patent/ATE312096T1/de not_active IP Right Cessation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events